Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamisil
Drug ID BADD_D01241
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]
Marketing Status approved; investigational; vet_approved
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02219
MeSH ID D000077291
PubChem ID 1549007
TTD Drug ID D01AYJ
NDC Product Code 71205-152; 71335-1668; 69097-859; 62135-572; 63187-213; 76282-209; 72189-243; 59349-0008; 70518-1191
UNII G7RIW8S0XP
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H26N+
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CC[NH+](C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza11.05.03.001; 22.07.02.001---
Influenza like illness08.01.03.010--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Laryngeal pain22.12.03.010--
Liver disorder09.01.08.001---
Malaise08.01.01.003--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Neutropenia01.02.03.004---
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003---
Paraesthesia17.02.06.005; 23.03.03.094--
Photosensitivity reaction23.03.09.003--
Polymorphic light eruption23.03.09.008---
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002---
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rhabdomyolysis15.05.05.002--
Rhinorrhoea22.12.03.021--
Serum sickness10.01.03.004; 12.02.08.004--
Serum sickness-like reaction08.01.03.003; 10.01.03.005---
Skin discolouration23.03.03.005---
Skin disorder23.03.03.007---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages